ArticleEMBO molecular medicine2023
Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine.
Article in EMBO molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Immunological and antitumor responses to HPV-targeted therapeutic vaccines in preclinical models of head and neck cancer: a systematic review.Cancer metastasis reviews · 2026Pooled it
- Eradication of pre-clinical prostate tumors by a lentiviral vector-based immunotherapy.Molecular therapy. Oncology · 2026Article
- Bidirectional Interactions Between Cervicovaginal Microbiota and Human Papillomavirus Drive Persistence and Disease Progression.International journal of molecular sciences · 2026Review
- Development and preclinical evaluation of KDTV001, an adenovirus 5-vectored trivalent HPV therapeutic vaccine targeting HPV16/18/52.EBioMedicine · 2026Article
- Application Advances of Lentiviral Vectors: From Gene Therapy to Vaccine Development.Molecular biotechnology · 2026Review
- Head and neck cancer therapeutic vaccines: a review.Frontiers in oncology · 2026Review
- HPV Vaccine: An Effective but Underutilized Prevention Tool.International journal of environmental research and public health · 2025Article
- Lentiviral Vectors: From Wild-Type Viruses to Efficient Multi-Functional Delivery Vectors.International journal of molecular sciences · 2025Review
- Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity.NPJ vaccines · 2025Article
- A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy.Scientific reports · 2025Article
- Differential predictive value of resident memory CD8Journal for immunotherapy of cancer · 2024Article
- T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector.NPJ vaccines · 2024Article
- Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine.EMBO molecular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
Human papillomavirus (HPV) infections are the cause of all cervical and numerous oropharyngeal and anogenital cancers. The currently available HPV vaccines, which induce neutralizing antibodies, have no therapeutic effect on established tumors. Here, we developed an immuno-oncotherapy against HPV-induced tumors based on a non-integrative lentiviral vector encoding detoxified forms of the Early E6 and E7 oncoproteins of HPV16 and 18 genotypes, namely, "Lenti-HPV-07". A single intramuscular injection of Lenti-HPV-07 into mice bearing established HPV-induced tumors resulted in complete tumor eradication in 100% of the animals and was also effective against lung metastases. This effect correlated with CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.